The company said, “As previously announced, Equillium (EQ) had no further intention to continue development of itolizumab, therefore on September 30, 2025, Biocon and Equillium entered into an agreement to terminate their collaboration and license agreement and other agreements relating to itolizumab.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EQ:
- Equillium Files Prospectus for $75 Million Stock Sale
- Equillium files to sell 52.63M shares of common stock for holders
- Equillium Regains Nasdaq Compliance with Bid Price Rule
- Equillium price target lowered to $4 from $8 at Jefferies
- Equillium’s Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial Uncertainties